Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
NCT04231864 · Alain Algazi · PHASE2 · withdrawn · last registry update 2020-10-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Feasibility” | – | Registry record, Alain Algazi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-10-26Phase 3 first posted: National Cancer Institute (NCI), Avelumab + Cabozantinib S-malate (NCT05092958)
- 2021-10-25Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Lurbinectedin (NCT05091567)
- 2021-10-01Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab + Bevacizumab (NCT05063552)
- 2021-09-28Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab + Carboplatin (NCT05058651)
- 2021-09-28Phase 3 first posted: Pfizer, Avelumab + Lorlatanib (NCT05059522)
- 2021-09-17Phase 3 first posted: Hoffmann-La Roche, Atezolizumab (NCT05047250)
- 2021-09-13Phase 3 first posted: AstraZeneca, savolitinib + durvalumab (NCT05043090)
- 2021-05-05Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Trastuzumab Emtansine (NCT04873362)
- 2021-01-15Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Becavizumab (NCT04712643)
- 2020-12-14Phase 3 first posted: Hoffmann-La Roche, Tiragolumab + Atezolizumab (NCT04665856)
- 2020-12-09Phase 3 first posted: Hoffmann-La Roche, Atezolizumab (NCT04660344)
- 2020-11-16Phase 3 first posted: National Cancer Institute (NCI), Cisplatin + Doxorubicin Hydrochloride (NCT04628767)
- 2020-10-14Phase 3 first posted: Stanford University, Durvalumab + Carboplatin (NCT04585490)
- 2020-09-16Phase 3 first posted: AstraZeneca, Durvalumab + Placebo (NCT04550260)
- 2020-09-10Phase 3 first posted: Hoffmann-La Roche, Tiragolumab + Atezolizumab (NCT04543617)
- 2020-08-12Phase 3 first posted: SWOG Cancer Research Network, Active Comparator (NCT04510597)
- 2020-05-27Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab (NCT04402788)
- 2020-04-06Phase 3 first posted: PrECOG, LLC., Durvalumab + Standard Chemotherapy (NCT04334759)
- 2020-03-04Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT04294810)
- 2020-02-13Phase 3 first posted: AstraZeneca, olaparib + durvalumab (NCT04269200)
- 2020-01-02Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab (NCT04214262)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision